Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery.

Area of Science:

• Computational chemistry and molecular modeling
• Pharmacology and drug discovery
• Systems biology and disease networks

Background:

• Modern drug discovery is rapidly evolving due to advancements in molecular modeling, big data analytics, and high-speed computing.
• Research increasingly focuses on protein-protein interaction (PPI) systems implicated in diseases like cancer, neurological disorders, and metabolic conditions.
• Targeting PPIs presents significant challenges due to their inherently "undruggable" binding interfaces.

Purpose of the Study:

• To review current obstacles hindering drug discovery targeting protein-protein interactions.
• To highlight how recent in silico approaches and discoveries can overcome these barriers.
• To discuss existing data on PPI compounds and their utility in molecular modeling for drug discovery.

Main Methods:

• Review of current literature on protein-protein interaction (PPI) drug discovery.
• Analysis of advancements in in silico approaches, including molecular modeling and big data analytics.
• Examination of exemplary studies demonstrating the application of computational methods in PPI targeting.

Main Results:

• In silico approaches show significant promise in alleviating barriers to targeting 'undruggable' PPIs.
• Computational tools expedite the identification and development of potential drug leads for PPI-related diseases.
• Existing data on PPI compounds and systems are valuable resources for molecular modeling applications.

Conclusions:

• In silico methods are crucial for advancing drug discovery in the complex field of protein-protein interactions.
• Despite limitations, computer-aided drug discovery offers a powerful perspective for tackling challenging disease targets.
• Further integration of computational approaches is essential for future breakthroughs in PPI-targeted therapeutics.